This study is for women aged 45-60 experiencing vasomotor symptoms (hot flashes) due to menopause. Vasomotor symptoms are sudden feelings of warmth, usually in the upper body. The study tests a drug called NOE-115, which is a monoamine modulator—a type of medicine that affects brain chemicals. This study checks if NOE-115 is safe and works well for these symptoms. Women will participate for about 12 weeks: 4 weeks of screening, 4 weeks of treatment, and 4 weeks of follow-up. There are two groups (cohorts) in the study. Cohort 1 gets a set dose of the drug first. After checking safety, Cohort 2 may have their dose adjusted. Participants return to the clinic on specific days for check-ups.
- Study spans around 12 weeks including screening, treatment, and follow-up.
- Participants receive NOE-115 daily for 4 weeks.
- Regular clinic visits are required for safety checks.
How understandable was the trial content above?
Hard to understand
Easy to understand